Relmada Therapeutics GAAP EPS of -$0.12 beats by $0.02

Relmada Therapeutics reported Q3 GAAP EPS of -$0.12, exceeding estimates by $0.02. The company's cash and investments rose to $202.1M as of September 30, 2026, up from $93.0M at the end of 2025, according to its press release.

Original reporting
Published Nov 12, 2026, 9:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 10:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$RLMD
Neutral
medium confidence
Mentioned
$RLMD
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$RLMDNeutralLow
01

Why it matters

The earnings beat is modest and unlikely to trigger a significant price move, but improved cash may support near‑term operations.

02

Market read

Micro‑cap earnings beat with limited market impact.

03

What to watch

Potential upcoming clinical trial milestones could drive future volatility beyond the earnings beat.

Relevance 6/10Novelty 7/10Timing: today

Background

Relmada Therapeutics is a clinical‑stage biopharma focused on CNS disorders. The company posted a cash balance of $202.1 million at quarter‑end.

Company-level read

Ticker impact

$RLMDNeutralMedium confidence
Context

Relmada Therapeutics reported Q3 GAAP EPS of -$0.12, beating expectations by $0.02.

Expected impact

likely modest upward pressure as market prices in the earnings beat

Evidence & confidence

EPS beat is small and cash position improved, but the company remains a microcap with limited liquidity.

Market effects

Minimal impact on the broader biotech sector; earnings beat is company‑specific.

Limited to U.S. micro‑cap investors; no broader regional effect.

None

Counterpoint

The EPS beat may be outweighed by ongoing cash burn and limited pipeline progress.

Key entities

  • Relmada Therapeutics

    Biopharma reporting Q3 earnings.

Related articles

$RLMDMedAI 8/10

Relmada (RLMD) Q3 2026 Earnings Call Transcript

Relmada (RLMD) reported Q3 2026 progress, including IND submissions for NDV-01 and sepranolone by year-end. NDV-01 showed 86% 18-month CR rate in NMIBC, with favorable safety. Phase 3 trials planned. Cash position of $202.1M expected to fund operations through 2029. Net loss was $13.9M, up from $10.1M YoY.

$RLMDHigh

Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

RELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update ● NDV-01 CMC program on track to submit the IND by year-end 2026, with initiation of the registrational Phase 3 SPECTRUM program upon IND clearance ● Long-term extension ND

$RLMDMed

Relmada (RLMD) Q2 2026 Earnings Call Transcript

Relmada Therapeutics (RLMD) reported Q2 2026 results and an execution update. Cash was $217.7M at June 30, 2026, funding operations through 2029. Net loss was $12.9M ($0.11/share). Management expects IND filings for NDV-01 and sepranolone by end-2026 and Phase 3 RESCUE enrollment to start after IND clearance.

$RLMDMed

Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

RELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update ● Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational

$WMTHighAI 8/10

Walmart Has Raised Its Dividend 53 Straight Years. I'd Buy It Before December and Never Sell.

Walmart (WMT) reported better-than-expected sales and profits, raised its full-year forecast, and announced 53 consecutive years of dividend increases. Despite this, its stock fell 2% in early trading. The company's omnichannel model, advertising business, and AI shopping assistant contributed to its growth, while rising diesel prices and slowing same-store sales growth pose challenges. Walmart's dividend is payable to shareholders of record on December 11.